TICEBA is a bio-pharmaceutical company and the first state-of-the-art tissue bank for stem cells derived from the skin worldwide and has developed into one of the leading laboratories for tissue and stem cell banking as well as for developing stem cell based therapies worldwide. Phase I/IIa clinical trials are ongoing with the indications of chronic venous ulcers (CVU), diabetic foot ulcers (DFU), peripheral arterial occlusive disease (PAOD) and since November 2018 for the indication recessive dystrophic epidermolysis bullosa (RDEB). Further clini-cal trials are in the application phase. TICEBA produces stem cells of the highest quality as pharmaceuticals (§13 AMG) for its subsidiary RHEACELL GmbH & Co. KG.